<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:49:34 -0700</creation_date>
  <update_date>2013-05-27 11:07:35 -0600</update_date>
  <accession>HMDBP00272</accession>
  <secondary_accessions>
    <accession>5504</accession>
    <accession>HMDBP03762</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
  </synonyms>
  <gene_name>COMT</gene_name>
  <general_function>Involved in magnesium ion binding</general_function>
  <specific_function>Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Tyrosine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00350</kegg_map_id>
    </pathway>
    <pathway>
      <name>Dopaminergic synapse</name>
      <smpdb_id/>
      <kegg_map_id>map04728</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00022</accession>
      <name>3-Methoxytyramine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01336</accession>
      <name>3,4-Dihydroxybenzeneacetic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01866</accession>
      <name>3,4-Dihydroxymandelic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00318</accession>
      <name>3,4-Dihydroxyphenylglycol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00073</accession>
      <name>Dopamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00068</accession>
      <name>Epinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00118</accession>
      <name>Homovanillic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB04063</accession>
      <name>Metanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00216</accession>
      <name>Norepinephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00819</accession>
      <name>Normetanephrine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00291</accession>
      <name>Vanillylmandelic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01490</accession>
      <name>Vanylglycol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00547</accession>
      <name>Magnesium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01185</accession>
      <name>S-Adenosylmethionine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00010</accession>
      <name>2-Methoxyestrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00957</accession>
      <name>Pyrocatechol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00939</accession>
      <name>S-Adenosylhomocysteine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01398</accession>
      <name>Guaiacol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00181</accession>
      <name>L-Dopa</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00883</accession>
      <name>L-Valine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00333</accession>
      <name>Isohomovanillic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00380</accession>
      <name>2-Hydroxyestradiol-3-methyl ether</name>
    </metabolite>
    <metabolite>
      <accession>HMDB12226</accession>
      <name>Entacapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14400</accession>
      <name>Diethylstilbestrol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14468</accession>
      <name>Tolcapone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14979</accession>
      <name>Dobutamine</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15272</accession>
      <name>Micafungin</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00343</accession>
      <name>2-Hydroxyestrone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00338</accession>
      <name>2-Hydroxyestradiol</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00405</accession>
      <name>2-Methoxyestradiol</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transferase activity, transferring one-carbon groups</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>methyltransferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>o-methyltransferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catechol o-methyltransferase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>magnesium ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological quality</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of neurotransmitter levels</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>neurotransmitter metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>neurotransmitter catabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid and derivative metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular amino acid derivative metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular biogenic amine metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>catecholamine metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>intracellular membrane-bounded organelle</description>
      <go_id>GO:0043231</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>mitochondrion</description>
      <go_id>GO:0005739</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>plasma membrane</description>
      <go_id>GO:0005886</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>catechol O-methyltransferase activity</description>
      <go_id>GO:0016206</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>magnesium ion binding</description>
      <go_id>GO:0000287</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>O-methyltransferase activity</description>
      <go_id>GO:0008171</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>dopamine catabolic process</description>
      <go_id>GO:0042420</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>estrogen metabolic process</description>
      <go_id>GO:0008210</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>female pregnancy</description>
      <go_id>GO:0007565</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>learning</description>
      <go_id>GO:0007612</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>multicellular organismal reproductive process</description>
      <go_id>GO:0048609</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of dopamine metabolic process</description>
      <go_id>GO:0045963</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of smooth muscle cell proliferation</description>
      <go_id>GO:0048662</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter biosynthetic process</description>
      <go_id>GO:0042136</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>neurotransmitter catabolic process</description>
      <go_id>GO:0042135</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of homocysteine metabolic process</description>
      <go_id>GO:0050668</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to drug</description>
      <go_id>GO:0042493</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to lipopolysaccharide</description>
      <go_id>GO:0032496</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to organic cyclic compound</description>
      <go_id>GO:0014070</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to pain</description>
      <go_id>GO:0048265</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>xenobiotic metabolic process</description>
      <go_id>GO:0006805</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Isoform Membrane-bound:Cell membrane</subcellular_location>
    <subcellular_location>Single-pass type II membrane protein</subcellular_location>
    <subcellular_location>Extracellular side</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>22</chromosome_location>
    <locus>22q11.21</locus>
    <gene_sequence>&gt;816 bp
ATGCCGGAGGCCCCGCCTCTGCTGTTGGCAGCTGTGTTGCTGGGCCTGGTGCTGCTGGTG
GTGCTGCTGCTGCTTCTGAGGCACTGGGGCTGGGGCCTGTGCCTTATCGGCTGGAACGAG
TTCATCCTGCAGCCCATCCACAACCTGCTCATGGGTGACACCAAGGAGCAGCGCATCCTG
AACCACGTGCTGCAGCATGCGGAGCCCGGGAACGCACAGAGCGTGCTGGAGGCCATTGAC
ACCTACTGCGAGCAGAAGGAGTGGGCCATGAACGTGGGCGACAAGAAAGGCAAGATCGTG
GACGCCGTGATTCAGGAGCACCAGCCCTCCGTGCTGCTGGAGCTGGGGGCCTACTGTGGC
TACTCAGCTGTGCGCATGGCCCGCCTGCTGTCACCAGGGGCGAGGCTCATCACCATCGAG
ATCAACCCCGACTGTGCCGCCATCACCCAGCGGATGGTGGATTTCGCTGGCGTGAAGGAC
AAGGTCACCCTTGTGGTTGGAGCGTCCCAGGACATCATCCCCCAGCTGAAGAAGAAGTAT
GATGTGGACACACTGGACATGGTCTTCCTCGACCACTGGAAGGACCGGTACCTGCCGGAC
ACGCTTCTCTTGGAGGAATGTGGCCTGCTGCGGAAGGGGACAGTGCTACTGGCTGACAAC
GTGATCTGCCCAGGTGCGCCAGACTTCCTAGCACACGTGCGCGGGAGCAGCTGCTTTGAG
TGCACACACTACCAATCGTTCCTGGAATACAGGGAGGTGGTGGACGGCCTGGAGAAGGCC
ATCTACAAGGGCCCAGGCAGCGAAGCAGGGCCCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>271</residue_number>
    <molecular_weight>30036.77</molecular_weight>
    <theoretical_pi>5.467</theoretical_pi>
    <pfams>
      <pfam>
        <name>Methyltransf_3</name>
        <pfam_id>PF01596</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Catechol O-methyltransferase
MPEAPPLLLAAVLLGLVLLVVLLLLLRHWGWGLCLIGWNEFILQPIHNLLMGDTKEQRIL
NHVLQHAEPGNAQSVLEAIDTYCEQKEWAMNVGDKKGKIVDAVIQEHQPSVLLELGAYCG
YSAVRMARLLSPGARLITIEINPDCAAITQRMVDFAGVKDKVTLVVGASQDIIPQLKKKY
DVDTLDMVFLDHWKDRYLPDTLLLEECGLLRKGTVLLADNVICPGAPDFLAHVRGSSCFE
CTHYQSFLEYREVVDGLEKAIYKGPGSEAGP</protein_sequence>
  </protein_properties>
  <genbank_protein_id>180920</genbank_protein_id>
  <uniprot_id>P21964</uniprot_id>
  <uniprot_name>COMT_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>3A7E</pdb_id>
    <pdb_id>3BWM</pdb_id>
    <pdb_id>3BWY</pdb_id>
  </pdb_ids>
  <genbank_gene_id>M65212</genbank_gene_id>
  <genecard_id>COMT</genecard_id>
  <geneatlas_id>COMT</geneatlas_id>
  <hgnc_id>HGNC:2228</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I: Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 1991 Apr;10(3):181-9.</reference_text>
      <pubmed_id>1707278</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm HW, Malherbe P: Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1416-20.</reference_text>
      <pubmed_id>1847521</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tenhunen J, Salminen M, Lundstrom K, Kiviluoto T, Savolainen R, Ulmanen I: Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem. 1994 Aug 1;223(3):1049-59.</reference_text>
      <pubmed_id>8055944</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Collins JE, Wright CL, Edwards CA, Davis MP, Grinham JA, Cole CG, Goward ME, Aguado B, Mallya M, Mokrab Y, Huckle EJ, Beare DM, Dunham I: A genome annotation-driven approach to cloning the human ORFeome.  Genome Biol. 2004;5(10):R84. Epub 2004 Sep 30.</reference_text>
      <pubmed_id>15461802</pubmed_id>
    </reference>
    <reference>
      <reference_text>Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22.  Nature. 1999 Dec 2;402(6761):489-95.</reference_text>
      <pubmed_id>10591208</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vilbois F, Caspers P, da Prada M, Lang G, Karrer C, Lahm HW, Cesura AM: Mass spectrometric analysis of human soluble catechol O-methyltransferase expressed in Escherichia coli. Identification of a product of ribosomal frameshifting and of reactive cysteines involved in S-adenosyl-L-methionine binding. Eur J Biochem. 1994 Jun 1;222(2):377-86.</reference_text>
      <pubmed_id>8020475</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tilgmann C, Kalkkinen N: Purification and partial sequence analysis of the soluble catechol-O-methyltransferase from human placenta: comparison to the rat liver enzyme. Biochem Biophys Res Commun. 1991 Jan 31;174(2):995-1002.</reference_text>
      <pubmed_id>1993083</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ulmanen I, Lundstrom K: Cell-free synthesis of rat and human catechol O-methyltransferase. Insertion of the membrane-bound form into microsomal membranes in vitro. Eur J Biochem. 1991 Dec 18;202(3):1013-20.</reference_text>
      <pubmed_id>1765063</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rutherford K, Le Trong I, Stenkamp RE, Parson WW: Crystal structures of human 108V and 108M catechol O-methyltransferase.  J Mol Biol. 2008 Jun 27;380(1):120-30. Epub 2008 Apr 23.</reference_text>
      <pubmed_id>18486144</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM: Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996 Jun;6(3):243-50.</reference_text>
      <pubmed_id>8807664</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, Salonen JT, Ryynanen OP, Koulu M, Karvonen MK, Pohjalainen T, Syvalahti E, Hietala J: Association between the functional variant of the catechol-O-methyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry. 1999 May;4(3):286-9.</reference_text>
      <pubmed_id>10395222</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul;22(3):231-8.</reference_text>
      <pubmed_id>10391209</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lee SG, Joo Y, Kim B, Chung S, Kim HL, Lee I, Choi B, Kim C, Song K: Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum Genet. 2005 Mar;116(4):319-28. Epub 2005 Jan 12.</reference_text>
      <pubmed_id>15645182</pubmed_id>
    </reference>
    <reference>
      <reference_text>Rutherford K, Alphandery E, McMillan A, Daggett V, Parson WW: The V108M mutation decreases the structural stability of catechol O-methyltransferase. Biochim Biophys Acta. 2008 Jul-Aug;1784(7-8):1098-105. Epub 2008 Apr 24.</reference_text>
      <pubmed_id>18474266</pubmed_id>
    </reference>
    <reference>
      <reference_text>Annerbrink K, Westberg L, Nilsson S, Rosmond R, Holm G, Eriksson E: Catechol O-methyltransferase val158-met polymorphism is associated with abdominal obesity and blood pressure in men. Metabolism. 2008 May;57(5):708-11.</reference_text>
      <pubmed_id>18442637</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Ittiwut R, Listman JB, Ittiwut C, Cubells JF, Weiss RD, Brady K, Oslin D, Farrer LA, Kranzler HR, Gelernter J: Association between polymorphisms in catechol-O-methyltransferase (COMT) and cocaine-induced paranoia in European-American and African-American populations. Am J Med Genet B Neuropsychiatr Genet. 2011 Sep;156B(6):651-60. doi:       10.1002/ajmg.b.31205. Epub 2011 Jun 8.</reference_text>
        <pubmed_id>21656904</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Boot E, Booij J, Abeling N, Meijer J, da Silva Alves F, Zinkstok J, Baas F, Linszen D, van Amelsvoort T: Dopamine metabolism in adults with 22q11 deletion syndrome, with and without schizophrenia--relationship with COMT Val(1)(0)(8)/(1)(5)(8)Met polymorphism, gender and symptomatology. J Psychopharmacol. 2011 Jul;25(7):888-95. Epub 2011 Mar 29.</reference_text>
        <pubmed_id>21447540</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dopamine</name>
        <accession>HMDB00073</accession>
      </metabolite>
      <reference>
        <reference_text>Volavka J, Bilder R, Nolan K: Catecholamines and aggression: the role of COMT and MAO polymorphisms.  Ann N Y Acad Sci. 2004 Dec;1036:393-8.</reference_text>
        <pubmed_id>15817751</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>2-Hydroxyestradiol-3-methyl ether</name>
        <accession>HMDB00380</accession>
      </metabolite>
      <reference>
        <reference_text>Clemons M, Goss P: Estrogen and the risk of breast cancer.  N Engl J Med. 2001 Jan 25;344(4):276-85.</reference_text>
        <pubmed_id>11172156</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diethylstilbestrol</name>
        <accession>HMDB14400</accession>
      </metabolite>
      <reference>
        <reference_text>Engel LL, Weidenfield J, Merriam GR: Metabolism of diethylstilbestrol by rat liver: a preliminary report.  J Toxicol Environ Health Suppl. 1976;1:37-44.</reference_text>
        <pubmed_id>11352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Ries V, Selzer R, Eichhorn T, Oertel WH, Eggert K: Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. Clin Neuropharmacol. 2010 May;33(3):142-50.</reference_text>
        <pubmed_id>20502133</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Guay DR: Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease. Pharmacotherapy. 1999 Jan;19(1):6-20.</reference_text>
        <pubmed_id>9917075</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Keating GM, Lyseng-Williamson KA: Tolcapone: a review of its use in the management of Parkinson's disease.  CNS Drugs. 2005;19(2):165-84.</reference_text>
        <pubmed_id>15697329</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Truong DD: Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson's disease. Clin Interv Aging. 2009;4:109-13. Epub 2009 May 14.</reference_text>
        <pubmed_id>19503773</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Apud JA, Mattay V, Chen J, Kolachana BS, Callicott JH, Rasetti R, Alce G, Iudicello JE, Akbar N, Egan MF, Goldberg TE, Weinberger DR: Tolcapone improves cognition and cortical information processing in normal human subjects. Neuropsychopharmacology. 2007 May;32(5):1011-20. Epub 2006 Oct 25.</reference_text>
        <pubmed_id>17063156</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Stocchi F, De Pandis MF: Utility of tolcapone in fluctuating Parkinson's disease.  Clin Interv Aging. 2006;1(4):317-25.</reference_text>
        <pubmed_id>18046910</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT: Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat. J Pharmacol Exp Ther. 2003 Feb;304(2):498-506.</reference_text>
        <pubmed_id>12538800</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Tai CH, Wu RM: Catechol-O-methyltransferase and Parkinson's disease.  Acta Med Okayama. 2002 Feb;56(1):1-6.</reference_text>
        <pubmed_id>11873938</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Kaakkola S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs. 2000 Jun;59(6):1233-50.</reference_text>
        <pubmed_id>10882160</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tolcapone</name>
        <accession>HMDB14468</accession>
      </metabolite>
      <reference>
        <reference_text>Ruottinen HM, Rinne UK: COMT inhibition in the treatment of Parkinson's disease.  J Neurol. 1998 Nov;245(11 Suppl 3):P25-34.</reference_text>
        <pubmed_id>9808337</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Raxworthy MJ, Youde IR, Gulliver PA: Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52.</reference_text>
        <pubmed_id>2868577</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dobutamine</name>
        <accession>HMDB14979</accession>
      </metabolite>
      <reference>
        <reference_text>Yan M, Webster LT Jr, Blumer JL: Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro. J Pharmacol Exp Ther. 2002 Apr;301(1):315-21.</reference_text>
        <pubmed_id>11907189</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Micafungin</name>
        <accession>HMDB15272</accession>
      </metabolite>
      <reference>
        <reference_text>Groll AH, Stergiopoulou T, Roilides E, Walsh TJ: Micafungin: pharmacology, experimental therapeutics and clinical applications.  Expert Opin Investig Drugs. 2005 Apr;14(4):489-509.</reference_text>
        <pubmed_id>15882123</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Micafungin</name>
        <accession>HMDB15272</accession>
      </metabolite>
      <reference>
        <reference_text>Wiederhold NP, Lewis JS 2nd: The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety. Expert Opin Pharmacother. 2007 Jun;8(8):1155-66.</reference_text>
        <pubmed_id>17516879</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
